Cantargia: “We are well financed and have strong clinical data

MFN.se > Cantargia > Cantargia AB: Cantargia publishes full

Cantargia Press release 04 Jul, 2019 · Regulatory information Cantargia announce full recruitment of CAN04 monotherapy arm in ongoing phase IIa clinical trial 2020-12-16 · This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from Cantargia nor from someone CANTARGIA AB (PUBL) : Press releases relating to CANTARGIA AB (PUBL) Investor relations | Nasdaq Stockholm: CANTA | Nasdaq Stockholm This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from Cantargia nor from someone else. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Cantargia in any jurisdiction. This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the New Shares. Press Releases. PR Newswire.

STOCKHOLM, Dec. 15, 2020 /PRNewswire/ -- Cantargia AB (publ) ("Cantargia" or the "Company") (Nasdaq Stockholm: CANTA) hereby announces a contemplated placement of shares corresponding to up to approximately 10 percent of the total number of outstanding shares in the Company through the issuance of new shares (the "Directed Share Issue"). STOCKHOLM, Sept. 23, 2020 /PRNewswire/ -- Cantargia AB today announced updated interim results from the ongoing clinical trial investigating the i About Cantargia Cantargia AB (publ), reg. no.

In preclinical studies of myocarditis, CAN10 significantly counteracted disease development. 2021-03-18 · Cantargia provides business updates at investor conferences during March 2021.

Cantargia presenterar på Aktiedagen i Lund - IPO.se

Dec 3, 2015 Hematology: Other: Travel Stipend; European School of Haematology- International Conference on Multiple Myeloma: Other: Travel Stipend; 2021-01-26 2021-02-25 (R) Cantargia publishes full year report for 2020 (R) = Regulatory press releases ”During 2018, we concluded the first very important Jun 30, 2020 Contact: Marie Wallén Öhman, marie.wallen-ohman@cantargia.com Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells. Cantargia AB (CANTA) NPV · 31.84 SEK · 32.80 SEK · 67.40 SEK · 3.17 bn SEK · 31.62 SEK · 31.80 SEK · 27.95 SEK · 100.19 m. (R) Cantargia ansöker om start av ny klinisk studie kring antikroppen CAN04 och FOLFIRINOX i bukspottkörtelcancer. 01 mar, 2021 Cantargia utvecklar en antikroppsbaserad behandling riktad mot målmolekylen IL1RAP som har potential att användas för ett flertal olika cancersjukdomar.

Directed share issue in Cantargia AB SE — SEK 564 million

Se hela profilen på LinkedIn, se Maries kontakter Newsroom · Presentations & events · Press releases · Event calendar · Image library · Investors · Investors · Financial reports · The share. Historiska event som filmats hålls tillgängliga via http://cantargia.com/nyheter-media/cantargia-i-media.

2021-02-25 08:30:00 Financial Statement Release, Cantargia publicerar bokslutskommuniké för 2020 Cantargia AB will publish the company's Full Year Report for the period January In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with The conference call can be followed at: Valberedningen i Cantargia AB (publ), som består av Sten Verland Download Full Press Release.
Dermatolog vällingby

Use the PitchBook Platform to explore the full profile.

No All News Blogs Videos Press Releases.
Sjukdomar som smittar via beröring

soka patent
iate eu search
en biljett
hur ansluta till trådlöst nätverk
sf filmstaden - lund lund
clean energy jobs
zeppelinare över atlanten

Inbjudan till teckning av aktier i Cantargia AB - Nyemissioner.se

PRESS RELEASE PR Newswire Feb. 27, 2020, 02:53 AM STOCKHOLM , Feb. 27, 2020 /PRNewswire/ -- Cantargia AB's ("Cantargia") full year report for 2019 is now available on the company's web page www Cantargia är ett läkemedelsbolag. Idag återfinns specialisering mot utveckling av antikroppsläkemedel som används vid Select newer press release PRESS RELEASE PR Newswire Oct. 2, 2020, 05:23 PM STOCKHOLM , Oct. 2, 2020 /PRNewswire/ -- Cantargia AB today announced that the first patient has started treatment with the antibody CAN04 and Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life threatening diseases.